Circulating linoleic acid at the time of myocardial infarction and risk of primary ventricular fibrillation

Teresa Oliveras1,2,3,10, Iolanda Lázaro4,10, Ferran Rueda1,2,3, Germán Cediel1,2,3, Deepak L. Bhatt5, Montserrat Fitó6,5, Francisco Madrid-Gambín6,7, Oscar J. Pozo4, William S. Harris8,9, Cosme García-García1,2,3, Aleix Sala-Vila4,8,10 & Antoni Bayés-Genís1,2,3

Primary ventricular fibrillation (PVF) is a major driver of cardiac arrest in the acute phase of ST-segment elevation myocardial infarction (STEMI). Enrichment of cardiomyocyte plasma membranes with dietary polyunsaturated fatty acids (PUFA) reduces vulnerability to PVF experimentally, but clinical data are scarce. PUFA status in serum phospholipids is a valid surrogate biomarker of PUFA status in cardiomyocytes within a wide range of dietary PUFA. In this nested case-control study (n = 58 cases of STEMI-driven PVF, n = 116 control non-PVF STEMI patients matched for age, sex, smoking status, dyslipidemia, diabetes mellitus and hypertension) we determined fatty acids in serum phospholipids by gas-chromatography, and assessed differences between cases and controls, applying the Benjamini–Hochberg procedure on nominal P-values to control the false discovery rate (FDR). Significant differences between cases and controls were restricted to linoleic acid (LA), with PVF patients showing a lower level (nominal P = 0.002; FDR-corrected P = 0.027). In a conditional logistic regression model, each one standard deviation increase in the proportion of LA was related to a 42% lower prevalence of PVF (odds ratio = 0.58; 95% confidence interval, 0.37, 0.90; P = 0.02). The association lasted after the inclusion of confounders. Thus, regular consumption of LA-rich foods (nuts, oils from seeds) may protect against ischemia-driven malignant arrhythmias.

Coronary artery disease (CAD) remains a major health challenge and a top cause of global mortality1. Though advances in drugs and device-based therapies have largely reduced complications and improved outcomes for those who experience a myocardial infarction (MI), the rate of primary ventricular fibrillation (PVF) has remained stable over time2,3. PVF is a major trigger of out-of-hospital cardiac arrest leading to sudden cardiac death4, and patients developing ventricular fibrillation during acute MI are at higher risk of in-hospital mortality5. Therefore, novel strategies are needed to prevent and manage acute ischemic PVF.

Experimental research has been instrumental in understanding the arrhythmogenic mechanisms leading to PVF. In this regard, many metabolic and electrophysiological cardiac changes observed in the acute ischemic phase underlie disturbances in voltage-gated channels6. A large body of evidence indicates that polyunsaturated fatty acids (PUFA) acylated in the phospholipids constituting the lipid bilayers of cell membranes modulate the activity of voltage-gated channels by either altering the biophysical membrane properties (indirect effect) or binding to the protein upon cleavage from cell membrane phospholipids (direct effect)7,8. The finding that dietary fats are readily incorporated into the cell membranes of cardiomyocytes put for the hypothesis that sustained dietary PUFA intake and the ensuing enrichment in cardiac phospholipids might reduce myocardial vulnerability to early PVF in MI9.

1Department of Cardiology, Heart Institute, Hospital Universitari Germans Trias i Pujol, c/Canyet s/n, 08916 Badalona, Barcelona, Spain. 2Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. 3Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. 4Cardiovascular Risk and Nutrition–IMIM (Hospital del Mar Medical Research Institute), Dr. Aiguader 88, 08003 Barcelona, Spain. 5Brigham and Women’s Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA, USA. 6Centro de Investigación Biomédica en Red de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain. 7Signal and Information Processing for Sensing Systems, Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology, Barcelona, Spain. 8Fatty Acid Research Institute, Sioux Falls, SD, USA. 9Sanford School of Medicine, University of South Dakota, Sioux Falls, SD, USA. 10These authors contributed equally: Teresa Oliveras and Iolanda Lázaro. *email: 3aoliveras@gmail.com; asv@faresinst.com; abayesgenis@gmail.com
PUFA include mainly omega-3 (n-3) and omega-6 (n-6) fatty acids. n-3 PUFA, particularly those of marine origin (eicosapentaenoic acid [C20:5n-3, EPA] and docosahexaenoic acid [C22:6n-3, DHA]), have been shown to possess an array of cardioprotective effects. Regarding n-6 PUFA, in particular linoleic acid (C18:2n-6, LA), although sustained intake of LA has been mechanistically linked to an increased low-density lipoprotein oxidation and to the transformation to arachidonic acid (C20:4n-6, AA—a precursor of proinflammatory lipid mediators), there is increasing evidence of the cardioprotective benefits of LA intake within the range advocated by the American Heart Association. Experimental research uncovered a long time ago that replacement of saturated animal fat in the diet with either LA-rich or n-3-rich oils reduced the incidence and severity of arrhythmias occurring in ischemia. However, this notion barely translated into clinical research. We hypothesized that in patients with ST-elevation myocardial infarction (STEMI), cardiac enrichment in specific fatty acids resulting from the consumption of fat-rich foods during the weeks prior to the event would influence the vulnerability of the myocardium to develop PVF. To address this issue, at hospital admission for STEMI, we performed lipidomics in 58 patients who developed PVF and in 116 non-PVF controls matched for cardiovascular risk factors, searching for associations between fatty acid species and incident PVF. Given that routine myocardial biopsy is not safe in the acute phase of STEMI, we determined fatty acids in serum phospholipids, the status of which changes in parallel with heart phospholipids within a wide range of dietary fats.

### Results

Table 1 provides the participants' characteristics by study group. Per the study design, we found no differences in age, sex, smoking status, or prevalence of treated dyslipidemia, diabetes mellitus or hypertension. We neither observed differences in plasma concentrations of total cholesterol, triglycerides or other known risk factors for PVF as advanced Killip-Kimball class or anterior infarct location. When comparing serum phospholipids status of main fatty acids at hospital admission by study group, significant differences were restricted to LA, with PVF patients showing a lower compared with matched controls (nominal P value = 0.002; false discovery rate [FDR]-corrected P value = 0.027; Table 2 and Fig. 1). When assessing the odds ratios (OR) for the prevalence

| Variable                  | PVF cases (n = 58) | Non-PVF controls (n = 116) | P value |
|---------------------------|-------------------|---------------------------|---------|
| Demographics              |                   |                           |         |
| Age, years                | 59.9 ± 13.1       | 59.9 ± 12.6               | 0.99    |
| Female                    | 7 (12.1)          | 14 (12.1)                 | 1.00    |
| History                   |                   |                           |         |
| Smoking                   | 33 (56.9)         | 65 (56.0)                 | 0.91    |
| Hypertension              | 29 (50.0)         | 58 (50.0)                 | 1.00    |
| Diabetes mellitus         | 12 (20.7)         | 25 (21.6)                 | 0.89    |
| Dyslipidemia              | 35 (60.3)         | 64 (55.2)                 | 0.52    |
| Cerebrovascular disease   | 4 (6.9)           | 9 (7.8)                   | 0.84    |
| Myocardial infarction     | 8 (13.8)          | 8 (6.9)                   | 0.14    |
| PCI                       | 8 (13.8)          | 10 (8.6)                  | 0.29    |
| CABG                      | 0 (0)             | 0 (0)                     |         |
| Physical examination      |                   |                           |         |
| Killip-Kimball class III–IV | 6 (10.3)       | 5 (4.3)                   | 0.12    |
| BMI, kg/m²                 | 27.7 ± 5.2        | 27.3 ± 4.1                | 0.53    |
| Anterior infarct location | 29 (48.3)         | 46 (38.7)                 | 0.22    |
| Angiography, ≥ 70% stenosis | 58 (100)        | 114 (98.3)                | 0.48    |
| 0                         | 2 (3.4)           | 0 (0)                     | 0.04    |
| 1                         | 35 (60.3)         | 60 (51.7)                 | 0.28    |
| 2                         | 9 (15.5)          | 28 (24.1)                 | 0.19    |
| 3                         | 12 (20.7)         | 26 (22.4)                 | 0.79    |
| Successful primary PCI    | 55 (94.8)         | 106 (91.4)                | 0.42    |
| LVEF, %                   | 48.4 ± 10.6       | 51.8 ± 9.5                | 0.03    |

Table 1. Baseline characteristics of primary ventricular fibrillation (PVF) cases and matched controls. Data are presented as n (%), mean ± standard deviation, or median (interquartile range: Q1–Q3). BMI, body mass index; CABG, coronary artery bypass graft; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention. P value obtained by χ² test, Student's t test or Wilcoxon rank sum test, as appropriate.
of PVF associated with this PUFA, the unadjusted model (model 1) showed that each 1-standard deviation (SD) increase in the proportion of LA was related to a significant reduction (42%) in the prevalence of PVF (OR, 0.58; 95% confidence intervals [CI], 0.38 to 0.88; P = 0.01). The observed association remained essentially unchanged after the inclusion of confounders (Model 2, OR, 0.58; 95% CI, 0.37 to 0.90; P = 0.02). A non-linear pattern between LA and the odds of PVF was confirmed in an analysis using restricted cubic spline models that indicated a nadir of risk at 0 SD and decreasing odds of PVF at higher levels of LA (Fig. 2). Finally, the Spearman correlation coefficients for fatty acid species are shown in Fig. 3. We observed that n-6 PUFA were segregated in two groups. While ≥ 20-carbon species showed strong direct interrelationships (Spearman correlation coefficients ranging from 0.29 to 0.84), LA showed marginal and inverse associations with their longer-chain n-6 counterparts (Spearman correlation coefficient between LA and AA = − 0.17).

Table 2. Proportion of fatty acids in serum phospholipids in primary ventricular fibrillation (PVF) cases and matched controls at hospital admission for STEMI. Data are presented as mean ± standard deviation. Nominal P-values were assessed by Student’s t test, and the Benjamini–Hochberg procedure was applied on nominal P-values to control the false discovery rate (FDR).

| Fatty acid | PVF cases (n = 58) | Non-PVF controls (n = 116) | Nominal P-value | FDR-corrected P-value | Cohen’s d |
|------------|--------------------|---------------------------|-----------------|------------------------|-----------|
| C14:0      | 3.26 ± 2.09        | 2.90 ± 2.20               | 0.151           | 0.802                  | − 0.17    |
| C16:0      | 29.06 ± 3.62       | 28.55 ± 4.00              | 0.379           | 0.802                  | − 0.13    |
| C16:1n-7cis| 1.48 ± 1.21        | 1.33 ± 0.92               | 0.273           | 0.802                  | − 0.15    |
| C18:0      | 13.44 ± 3.62       | 12.96 ± 3.06              | 0.487           | 0.802                  | − 0.14    |
| C18:1n-9cis| 18.87 ± 6.65       | 18.16 ± 7.07              | 0.418           | 0.802                  | − 0.10    |
| C18:2n-6   | 17.00 ± 3.27       | 19.20 ± 4.53              | 0.002           | 0.027                  | 0.51      |
| C18:3n-3   | 0.28 ± 0.18        | 0.31 ± 0.42               | 0.513           | 0.802                  | 0.06      |
| C20:0      | 0.14 ± 0.08        | 0.13 ± 0.07               | 0.605           | 0.802                  | − 0.11    |
| C20:2n-6   | 0.29 ± 0.08        | 0.31 ± 0.09               | 0.250           | 0.802                  | 0.19      |
| C20:3n-6   | 2.56 ± 0.99        | 2.67 ± 1.11               | 0.752           | 0.802                  | 0.10      |
| C20:4n-6   | 8.62 ± 3.00        | 8.61 ± 3.35               | 0.668           | 0.802                  | − 0.01    |
| C20:5n-3   | 0.60 ± 0.37        | 0.56 ± 0.37               | 0.366           | 0.802                  | − 0.09    |
| C22:0      | 0.10 ± 0.05        | 0.12 ± 0.13               | 0.618           | 0.802                  | 0.14      |
| C22:4n-6   | 0.31 ± 0.13        | 0.31 ± 0.12               | 0.804           | 0.802                  | − 0.06    |
| C22:5n-3   | 0.22 ± 0.09        | 0.22 ± 0.10               | 0.610           | 0.802                  | − 0.06    |
| C22:5n-6   | 0.55 ± 0.16        | 0.54 ± 0.17               | 0.587           | 0.802                  | − 0.02    |
| C22:6n-3   | 3.14 ± 1.10        | 3.14 ± 1.23               | 0.755           | 0.802                  | 0.00      |

Figure 1. Serum phosphatidylcholine linoleic acid proportion by diagnosis of ventricular fibrillation.
Figure 2. Adjusted predictions with the 95% confidence interval for the relationship between standardized linoleic acid (C18:2n-6) values and the occurrence of primary ventricular fibrillation (PVF). Standardized C18:2n-6 values were modeled by restricted cubic splines. All predictors were set to their mean values.

Figure 3. Spearman correlation coefficients in all available fatty acid species in serum phospholipids.
Discussion

In this case–control, prospective study enrolling a large cohort of STEMI-driven PVF patients and matched non-PVF STEMI controls, we determined the fatty acid status of serum phospholipids at hospital admission for STEMI. These objective lipidomic biomarkers mirror not only dietary intake during the previous weeks, but also the fatty acid status in inner membranes, including cardiomycocytes. We found that a lower prevalence of PVF was associated with increasing levels of LA, an essential n-6 fatty acid naturally found in nuts (such as walnuts, pine nuts, pistachios and almonds) and seed oils (such as canola, corn, safflower, soybean, and sunflower oils).

Our findings are clinically relevant in two ways. First, we provide novel clinical evidence of a modifiable lifestyle (dietary) factor that is related to a lower risk of PVF, an endpoint that is a major contributor to short-term mortality in STEMI survivors. PVF is difficult to predict, and occurs at persistently high rates despite advances in the era of PPCI. Therefore, identifying any easily accessible and safe strategy to reduce the risk for PVF in STEMI patients is needed. Second, because LA in serum phospholipids reflects dietary levels of this essential fatty acid, we suggest that intake of this n-6 PUFA may protect against PVF. This observation was repeatedly reported in animal models and may be mechanistically explained by changes in membrane cellular fatty acid composition. Notably, because LA can be transformed into AA, a substrate of many proinflammatory lipid mediators, dietary LA is widely perceived to promote inflammation, contributing to cardiovascular disease. Although LA can be converted to a few inflammatory and vasoconstrictory lipid mediators, there is a growing body of evidence for the potential cardio-metabolic benefits of LA, including a recent landmark study pooling data from 30 prospective cohorts, which reported that higher in vivo circulating and tissue levels of LA were associated with lower risk of major cardiovascular events. Our data contribute to countering the demand to remove LA from the diet based on its proposed harmful effects. Indeed, seed oils that used to be rich sources of LA, such as safflower and sunflower oils, have now been hybridized to substantially remove LA. According to a recent modeling experiment, this shift may be placing the population (children in particular) at increased risk of a deficiency in essential fatty acids, including LA.

Interestingly, we failed to find significant associations for marine-derived n-3 fatty acids. Though a large body of observational evidence exists on the benefits of dietary EPA and DHA against sudden cardiac death, the issue of whether dietary EPA and DHA may protect against PVF in the setting of STEMI remains unsettled, with randomized controlled trials conducted in patients with chronic myocardial scars wearing implantable cardioverter defibrillators who already have a history of ventricular arrhythmia. Further research is warranted to clarify effects of dietary n-3 PUFA on PVF.

This study had several limitations. First, its observational nature precludes establishing causality between circulating LA (or dietary LA intake) and prevention of PVF in the setting of STEMI. Such a link could only be confirmed by a randomized controlled trial of dietary supplementation with LA before the occurrence of STEMI—which practically speaking would be challenging to design. Second, we used the fatty acid profile of serum phospholipids. Although the use of this lipidomic-based objective biomarker of long-term dietary fatty acid intake circumvents the disadvantages of self-reported dietary data (i.e., food diaries and food frequency questionnaires), the fatty acid profile of serum phospholipids does not reflect long-term intake as accurately as the fatty acids in adipose tissue or red blood cells. Third, dietary LA in Mediterranean populations is largely supplied by nuts and seeds, which contain many cardioprotective bioactive agents in addition to PUFA. Therefore, we cannot rule out the parent foods themselves being the actual protective agent and LA just a marker of their consumption. Finally, because some potential health-related confounding variables (i.e., socioeconomic status, education, adherence to Mediterranean diet) were not available, we could not exclude the possibility that uncaptured environmental factors may have influenced or caused the observed association.

In conclusion, we identified an association of elevated LA in serum phospholipids at the time of STEMI with a lower risk of PVF. Thus, sustained consumption of sources rich in LA may reduce the risk of ischemia-driven cardiac arrest. Our results, which concur with experimental data and suggested membrane-based benefits ascribed to dietary LA, contribute to dispel the notion that the entire n-6 family of fatty acids promote cardiovascular disease.

Methods

Study design and population. The study was a post-hoc, nested case–control study of participants included in the Ruti-STEMI biomarkers study between February 23, 2011, and January 30, 2016. The study included prospectively consecutive patients with STEMI in a stable and well-defined geographic area of approximately 850,000 inhabitants in the northern metropolitan area of Barcelona in Catalonia, Spain, within the Codi IAM primary percutaneous coronary intervention (PPCI) network. For the current analysis, only patients having a blood sample available for fatty acid measurement were considered (n = 944).

Cases (n = 58) consisted of all individuals diagnosed with PVF during the acute phase of STEMI. Controls were STEMI patients who did not develop PVF during the first 48 h after symptom onset. They were selected by matching two controls with each case using the following criteria: age (± 3 years), sex, smoking status, dyslipidemia, diabetes mellitus, and hypertension. A total of 116 controls were matched to cases (Supplementary Fig. S1).

The STEMI diagnosis was established according to the current universal definition of MI at the time of the study, which included chest pain and electrocardiogram showing ST-segment elevation in two or more contiguous leads (minimum 0.1 mV in the frontal leads and 0.2 mV in the precordial leads) or with new-onset left bundle branch block. Baseline demographics and clinical data were recorded during hospital admission.

In our present analysis, patients were classified according to whether they developed PVF in the first 48 h and included in-hospital (if occurring within hospital facilities before, during, or after PPCI up to 48 h after MI.
diagnosis) and out-of-hospital PVF (within the EMS system) when arriving alive to the hospital. Events beyond 48 h likely include secondary ventricular fibrillation in a dysfunctional myocardium and were not considered here.

The study was conducted in accordance with the guidelines of the Declaration of Helsinki and was approved by the local Ethics Committee (The Ethics Committee of the Clinical Investigation of Germans Trias i Pujol Hospital, reference EO-11-061). Patients or their representatives provided written informed consent.

**Laboratory measurements.** Blood samples were obtained from veno-puncture soon after admission and within 12 h after symptom onset. Samples were processed in a central laboratory to measure biomarkers. Serum was stored at −80 °C until fatty acid analysis. Total serum lipids were extracted with 2 mL of chloroform/methanol (2:1 v/v). After shaking, the mixture was centrifuged (5 min at 3500 rpm at room temperature), and the organic phase was transferred to a borosilicate glass tube and evaporated to dryness under N2 at 30°C. Phosphatidylcholine was isolated by solid-phase extraction as described in Burdge et al.26. Briefly, dried serum lipid extract was redissolved in dry chloroform and applied to an aminopropyl silica column (Sep-Pak Vac NH2 cartridges, 100 mg packed silica per 1 mL Waters) under gravity. After eluting neutral lipid fractions (namely cholesteryl esters and triglycerides), we collected phosphatidylcholine upon elution with a mixture of dry chloroform and methanol. The fraction was evaporated to dryness under N2 at 30°C, and fatty acids were then hydrolyzed and methylated by acidified methanol26. Briefly, 1 mL of dry methanol containing H2SO4 (2%) was added to the tube, which was capped and placed into a block heather (50 °C) for 2 h. After cooling, 80 µL of a solution containing K2CO3 and 500 µL of n-hexane were added. The tubes were shaken for 1 min, and then centrifuged for 5 min at 3500 rpm at room temperature to separate the layers. The hexane layer was transferred into an automatic injector vial equipped with a glass insert of 300 µL. Fatty acid methyl esters were injected into an Agilent HP 7890 Gas Chromatograph equipped with a 30 m × 0.25 mm × 0.25 mm SupraWAX-280 capillary column (Teknokroma, Barcelona, Spain), an autosampler, and flame ionization detection. Gas-chromatography was run using an optimized temperature program, as follows: the program started at 50 °C, held for 2 min and increased to 220 °C at a rate of 4 °C/min. Helium was used as a carrier gas (30 psi, constant pressure mode). Temperature of injector and detector was 260 °C. The amount of each fatty acid is expressed as a percentage of the total amount of fatty acids.

**Statistical analysis.** Summary statistics including counts and percentages are provided for categorical variables and both means with standard deviations and medians with interquartile ranges are provided for continuous variables. Categorical variables were compared using the χ² test. Continuous variables were compared using the Student’s t test or Wilcoxon rank sum test. Differences between PVF cases and matched controls for continuous variables and both means with standard deviations and medians with interquartile ranges are provided for conditional logistic regression model. In addition to an unadjusted model (model 1), a model adjusted for left ventricular ejection fraction, Killip–Kimball class and anterior infarct location (y/n) was also constructed (Model 2). ORs reflecting a change of one SD in a given fatty acid and the CIs are reported. Finally, the interrelationship between selected serum phospholipids PUFA was assessed using the Spearman rank correlation and plotted in heatmap format.

Differences were considered significant if P < 0.05. All analyses were performed in STATA V.13.0 (StataCorp, College Station, TX) or R Software version 4.0.3.28 Data described in the article will be made available upon request pending application and approval.

Received: 17 September 2021; Accepted: 21 February 2022

Published online: 14 March 2022

**References**

1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 396, 1204–1222 (2020) (Erratum in: Lancet 2020;396:1562).
2. Thompson, C. A. et al. Changes over time in the incidence and case-fatality rates of primary ventricular fibrillation complicating acute myocardial infarction: Perspectives from the Worcester Heart Attack Study. *Am. Heart. J.* 139, 1014–1021 (2000).
3. García-García, C. et al. Trends in short- and long-term ST-segment-elevation myocardial infarction prognosis over 3 decades: A Mediterranean population-based ST-segment-elevation myocardial infarction registry. *J. Am. Heart. Assoc.* 9, e017159. https://doi.org/10.1161/JAHA.120.017159 (2020).
4. Wong, C. X. et al. Epidemiology of sudden cardiac death: Global and regional perspectives. *Heart. Lung. Circ.* 28, 6–14 (2019).
5. Bougouin, W. et al. Incidence of sudden cardiac death after ventricular fibrillation complicating acute myocardial infarction: A 5-year cause-of-death analysis of the FAS-MI 2005 registry. *Eur. Heart. J.* 35, 116–122 (2014).
6. Sattler, S. M. et al. Ventricular arrhythmias in first acute myocardial infarction: Epidemiology, mechanisms, and interventions in large animal models. *Front. Cardiovac. Med.* 6, 158. https://doi.org/10.3389/fcvm.2019.00158 (2019).
7. Bohannon, B. M. et al. Polysaturated fatty acid analogues differentially affect cardiac NaV, CaV, and Kv channels through unique mechanisms. *Elife* 9, e51453. https://doi.org/10.7554/eLife.51453 (2020) (Erratum in: Elife, 9, e01441 (2020)).
8. Larsson, J. E., Frampton, D. J. A. & Lin, S. J. Polysaturated fatty acids as modulators of Kv7 channels. *Front. Physiol.* 11, 641. https://doi.org/10.3389/fphys.2020.00641 (2020).
9. Charnock, J. S. Lipids and cardiac arrhythmia. *Prog. Lipid. Res.* 33, 355–385 (1994).
Author contributions
I.L., A.S.-V. and A.B.-G. designed research; T.O., I.L., F.R., G.C., F.M.-G., O.J.P., C.G.-G., A.S.-V. and A.B.-G. conducted research; G.C. and F.M.-G. analyzed data or performed statistical analysis; T.O., I.L., D.L.B., M.F., W.S.H., A.S.-V. and A.B.-G. wrote the paper; A.B.-G. had primary responsibility for the final content. All the authors have read and approved the final manuscript.

Funding
Part of this work was supported by a grant from the California Walnut Commission (Folsom, CA, USA; to AS-V). AB-G is supported by ISCIII (PI17/01487, PI18/00256, and PIC18/00014) and CIBER Cardiovascular (CB16/11/00403) projects as a part of the National R&D&I Plan, and co-funded by ISCIII-Sub-Directorate General for Research Assessment and Promotion and the European Regional Development Fund (ERDF). The funding agencies had no input in the study design, data collection, analyses, or writing and submission of the manuscript.

Competing interests
DLB discloses the following relationships-Advisory Board: Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Level Ex, Medscape Cardiology, MyoKardia, PhaseBio, PLx Pharma, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medintelligence/
ReachMD (CME steering committees), MJH Life Sciences, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, MyoKardia, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Novo Nordisk, Takeda. WSH holds an interest in OmegaQuant Analytics, a lab that offers blood fatty acid testing; and is a member of the RB Schiff Science and Innovation Advisory Board. AS-V reports grants and support from the California Walnut Commission to attend professional meetings. AB-G reports grants and personal fees from AstraZeneca, Abbott, Boehringer-Ingelheim, Vifor, Novartis, Roche Diagnostics, and Critical Diagnostics. TO, IL, FR, GC, MF, FM-G, OJP and CG-G have no conflicts of interest.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-08453-0.

Correspondence and requests for materials should be addressed to T.O., A.S.-V. or A.B.-G.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022